Royal Bank of Canada’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Royal Bank of Canada’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,454	Closed	-$1.34M	–	7930
2023 Q1	$1.34M	Sell	12,454 -2,195	-15%	-$253K	﹤0.01%	3128
2022 Q4	$1.61M	Sell	14,649 -1,891	-11%	-$123K	﹤0.01%	3096
2022 Q3	$976K	Buy	16,540 +15,524	+1,528%	+$710K	﹤0.01%	3473
2022 Q2	$29K	Sell	1,016 -1,426	-58%	-$41.3K	﹤0.01%	5954
2022 Q1	$93K	Sell	2,442 -3,884	-61%	-$154K	﹤0.01%	5714
2021 Q4	$251K	Buy	6,326 +4,649	+277%	+$146K	﹤0.01%	5106
2021 Q3	$39K	Buy	1,677 +904	+117%	+$21.3K	﹤0.01%	6310
2021 Q2	$19K	Buy	+773	New	+$17.2K	﹤0.01%	6600

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Royal Bank of Canada's RXDX Position: Q2 2023 in Review

Royal Bank of Canada sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 12,454 shares — an estimated $1.34M sold.

Royal Bank of Canada first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $1.61M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Royal Bank of Canada reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Royal Bank of Canada sold 12,454 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.34M.
Royal Bank of Canada first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Royal Bank of Canada's Prometheus Biosciences, Inc. Common Stock position peaked at $1.61M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.